Close Menu

North America

The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.

All the tests are authorized for use by CLIA-certified labs, while Visby's test may also be performed in a point-of-care setting.

The rapid chromatographic immunoassay detects SARS-CoV-2 using a nasopharyngeal swab and returns results in 15 minutes.

Exact's planned acquisition of Ashion, a sequencing lab based in Arizona, builds on the company's licensing of the TARDIS liquid biopsy technology from TGen in January.

For the three months ended Jan. 31, the firm said revenues rose to $1.55 billion from $1.36 billion a year ago, beating analysts' average estimate of $1.44 billion.

The firm's stock price has dropped since the announcement that the agency would need additional information and it has paused test shipments.

Binx Health said the initial distribution of its platform will be to settings certified to perform moderate- or high-complexity diagnostic tests under CLIA.

BioIQ will offer Fulgent's next-generation sequencing-based coronavirus assay on its diagnostic testing platform.

The companies will work together to offer rapid SARS-CoV-2 antigen testing for travelers in the US, Mexico, Canada, and the Caribbean.

The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit can detect and differentiate RNA from SARS-CoV-2, influenza A, and influenza B viruses.